|Bid||0.00 x 1800|
|Ask||0.00 x 2200|
|Day's Range||16.20 - 16.75|
|52 Week Range||11.15 - 31.97|
|Beta (5Y Monthly)||1.14|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Nov. 10, 2010|
|1y Target Est||26.76|
Agreement Includes Global Rights for Risuteganib, An Investigational Treatment Expected to Help Reverse Vision Loss Due to Dry AMD, A Significant Unmet Medical NeedLAVAL, QC and SAN JUAN CAPISTRANO, Calif., Sept.
And Allegro Ophthalmics, LLC (Allegro), a privately held biopharmaceutical company focused on the development ...
LAVAL, Quebec, Sept. 16, 2020 /CNW/ -- Bausch Health Companies Inc.